[Effectiveness of peg-interferon and ribavirin for hepatitis C in a patient with hypertension and diminished kidney function].
The treatment of chronic hepatitis caused by hepatitis C virus (HCV) has got now success only in 40-60 per cent of cases with combined interferon and ribavirin therapy. In patients infected by HCV not only the liver but other organs can have alterations. The treatment should be generally applied in a one-year period, and its administration should be carefully carried out both by the patients and the doctors. It can be accompanied by several complications. Beside these the other diseases of the patient's organs can have some problems.


OBJECTIVE
The demonstration of a patient history with clinical success who had hypertension and renal disease.


METHODS
42-year-old female patient who had hypertension and kidney diseases in her anamnesis. Her complaints started with mild abdominal symptoms in 2000. The biochemical alterations and the positive reaction with HCV-PCR test showed HCV infection. Its genotype was 1b. The patient tolerated the combined peginterferon-alfa-2a and ribavirin treatment well, between August 2006 and August 2007. She became HCV-PCR negative after six-month treatment and also at the end of therapy.


CONCLUSIONS
The concomitant diseases of the patient made the treatment heavier, but not impossible.


CONCLUSIONS
The elimination of HCV infection can be possible also in the case of hypertension and decreased renal function.
Bátyi
Eva
E
Jósa András Oktató Kórház, Belgyógyászati Osztály, Nyíregyháza, Szent István u. 68, 4400. batyieva@freemail.hu
Szegedi
János
J
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000503:physiopathology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000503:physiopathology; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a